Analyst Rating Update on Sarepta Therapeutics (SRPT)

Sarepta Therapeutics (NASDAQ:SRPT) : 3 brokerage houses believe that Sarepta Therapeutics (NASDAQ:SRPT) is a Strong Buy at current levels. 1 Analyst considers the fundamentals to be worthy of a Buy recommendation. 5 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Sarepta Therapeutics (NASDAQ:SRPT). Zacks Investment Research suggests a Hold with a rank of 3. 1 analysts perceive the stock to be overvalued at the existing levels, hence their call is to Sell the stock. 3 others believe that the stock has run up ahead of its fundamentals and advise a Strong Sell on the stock.The median of all the 13 Wall Street Analysts endorse the stock as a Hold with a rating of 3.

Sarepta Therapeutics (NASDAQ:SRPT) : 12 Wall Street analysts covering Sarepta Therapeutics (NASDAQ:SRPT) believe that the average level the stock could reach for the short term is $21.92. The maximum price target given is $60 and the minimum target for short term is around $4, hence the standard deviation is calculated at $16.39.

Company shares have received an average consensus rating of Hold for the current week Also, Brokerage firm Wedbush upgrades its rating on Sarepta Therapeutics (NASDAQ:SRPT). As per the latest information, the brokerage house raises the price target to $36 per share from a prior target of $14. The shares have been rated Outperform. Previously, the analysts had a Neutral rating on the shares. The rating by the firm was issued on June 7, 2016.

Sarepta Therapeutics (NASDAQ:SRPT): stock turned positive on Tuesday. Though the stock opened at $17.05, the bulls momentum made the stock top out at $17.89 level for the day. The stock recorded a low of $17.05 and closed the trading day at $17.81, in the green by 5.07%. The total traded volume for the day was 1,954,947. The stock had closed at $16.95 in the previous days trading.

In an insider trading activity, Behrens M Kathleen, director of Sarepta Therapeutics, Inc., executed a transaction worth $1,165,500 on March 14, 2016. A total of 75,000 shares were purchased at an average price of $15.54. The Insider information was divulged by the Securities and Exchange Commission in a Form 4 filing. The information is based on open market trades at the market prices.Option exercises are not covered.

Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of unique ribonucleic acid (RNA-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company is primarily focused on advancing the development of its potentially disease-modifying Duchenne Muscular Dystrophy (DMD) drug candidates, including its lead DMD product candidate, eteplirsen, which is an antisense PMO therapeutic in Phase III clinical development for the treatment of individuals with DMD who have an error in the gene coding for dystrophin that is amenable to skipping exon 51. The Company is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious, rare and other human diseases.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.